The law, slated to take effect in September, requires health plans to cover the treatment given by in-network providers, not ...

Using 400 real-world patient cases, the CARE platform correctly classified 99.5 percent of cases according to NCCN guidelines ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

The study will use a companion lipid biomarker test to identify those with a poor prognosis who are potential best responders.

The study also included older children and found the best outcomes in patients between 5 years and 8 years old.

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

A legislative ban on pharma ads, a tool for companies to amplify messaging on drugs, including for precision medicines, is ...

D Molecular Therapeutics said it is streamlining operations to offset expected expenses as it accelerates the timelines for its Phase III trials.

NEW YORK – Ensem Therapeutics on Tuesday said it dosed the first patient in a Phase I/II trial of the mutant-selective PI3kα inhibitor ETX-636 in patients with solid tumors. ETX-636 is designed to ...

NEW YORK – The European Commission has granted conditional approval to Jazz Pharmaceuticals' Ziihera (zanidatamab) for previously treated patients with unresectable, locally advanced or metastatic ...

NEW YORK – Neurogene this week said it has taken steps to begin a registrational trial to evaluate NGN-401, its investigational gene therapy for Rett syndrome, after reaching an agreement with the US ...